Sarepta Therapeutics Class Action Overview
The Gross Law Firm has issued a vital notice for shareholders of Sarepta Therapeutics, Inc. (NASDAQ: SRPT). This is particularly important for those who acquired shares within a specific timeframe and may be eligible for recovery in a recent class action lawsuit.
Class Period and Allegations
Shareholders who purchased SRPT shares from June 22, 2023, to June 24, 2025, are urged to get in touch with the firm to discuss potential lead plaintiff appointments. Being appointed as a lead plaintiff is not a requirement to participate in the recovery process.
The allegations against Sarepta suggest that significant safety risks were associated with ELEVIDYS, a gene therapy aimed at treating Duchenne muscular dystrophy. It is claimed that essential trial protocols failed to identify serious side effects, leading to grave concerns over the therapy's safety. Furthermore, it is asserted that adverse events from ELEVIDYS would eventually necessitate stopping participant recruitment and dosing in ongoing trials, thus drawing regulatory scrutiny and heightening risk regarding both current and future therapy approvals.
Important Dates for Shareholders
The crucial deadline for registering for this class action is August 25, 2025. Shareholders should not hesitate to enter their details as the clock is ticking on this timeline.
Once registered, shareholders will benefit from a specialized portfolio monitoring system that keeps them informed throughout the litigation process. The firm emphasizes that there are no costs or obligations involved in participation.
Why Choose The Gross Law Firm?
The Gross Law Firm is known nationally for its commitment to safeguarding investor rights, particularly for those affected by deceptive or fraudulent business practices. Their dedication lies in striving for accountability from companies like Sarepta that may mislead investors through inaccurate information or a lack of essential disclosures. The firm aims to recover losses incurred from inflated stock prices caused by these misstatements.
Contact Information
Investors wishing to gather more information or engage in this class action can simply reach out to the Gross Law Firm. The firm is located at:
The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY 10018
Phone: (646) 453-8903
Frequently Asked Questions
What is the class action about?
The class action involves allegations against Sarepta Therapeutics regarding the safety of their gene therapy, ELEVIDYS, and misleading statements regarding its trials.
Who can participate in the class action?
Shareholders who purchased shares of SRPT between June 22, 2023, and June 24, 2025, can register to participate in the lawsuit.
What is the registration deadline?
The deadline to register for the class action is August 25, 2025.
Are there any costs to participate?
No, there is no cost or obligation for shareholders to participate in this case.
How will I be informed about the case updates?
Once registered, shareholders will be enrolled in a portfolio monitoring system that provides status updates during the course of the litigation.
